Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Penyan Kangning capsule is a Traditional Chinese Medicine (TCM) formulation being developed for the treatment of chronic pelvic pain (CPP) resulting from the sequelae of pelvic inflammatory disease (PID). It is specifically indicated for patients presenting with the TCM syndrome of damp-heat and blood stasis (湿热瘀结证). The drug is currently undergoing Phase II clinical evaluation in China to assess its efficacy and safety in reducing pain symptoms and improving the quality of life for affected patients. It is co-developed by the Xi'an Shangyikang Pharmaceutical Research Institute and Huachuang Synthetic Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Penyan Kangning capsule.